Statements (72)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:activities |
ALK inhibitor
|
| gptkbp:appointed_by |
oral tablet
|
| gptkbp:approves |
gptkb:2014
gptkb:FDA |
| gptkbp:brand |
gptkb:Zykadia
|
| gptkbp:clinical_trial |
Phase 1
Phase 2 Phase 3 |
| gptkbp:contraindication |
severe liver impairment
|
| gptkbp:developed_by |
gptkb:Novartis
|
| gptkbp:dosage_form |
gptkb:tablet
|
| gptkbp:duration |
until disease progression
|
| gptkbp:excretion |
urine
bile |
| gptkbp:formulation |
film-coated tablet
|
| https://www.w3.org/2000/01/rdf-schema#label |
Ceritinib
|
| gptkbp:indication |
gptkb:ALK-positive_metastatic_NSCLC
|
| gptkbp:ingredients |
C21 H22 Cl N5 O2 S
|
| gptkbp:interacts_with |
CY P3 A4 inducers
CY P3 A4 inhibitors |
| gptkbp:is_monitored_by |
electrolytes
liver function tests complete blood count |
| gptkbp:is_used_for |
gptkb:healthcare_organization
|
| gptkbp:lifespan |
31 hours
|
| gptkbp:manager |
oral
|
| gptkbp:packaging |
gptkb:beer
|
| gptkbp:population |
adults
pediatric patients |
| gptkbp:safety_features |
hypersensitivity reactions
pregnancy category D QT prolongation risk alopecia risk anemia risk anxiety risk cardiac toxicity risk constipation risk depression risk diarrhea risk dizziness risk fatigue risk gastrointestinal toxicity risk headache risk hyperglycemia risk hypokalemia risk hypomagnesemia risk hypophosphatemia risk insomnia risk interstitial lung disease risk lactation caution mood changes risk nausea risk neutropenia risk peripheral neuropathy risk pulmonary toxicity risk rash risk renal toxicity risk thrombocytopenia risk visual disturbances risk vomiting risk weight gain risk weight loss risk |
| gptkbp:side_effect |
fatigue
nausea diarrhea liver enzyme elevation |
| gptkbp:storage |
room temperature
|
| gptkbp:targets |
gptkb:anaplastic_lymphoma_kinase_(ALK)
|
| gptkbp:weight |
393.95 g/mol
|
| gptkbp:bfsParent |
gptkb:Genzyme_Genetics
|
| gptkbp:bfsLayer |
5
|